Full Text View
Tabular View
No Study Results Posted
Related Studies
An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens
This study has been completed.
Study NCT00000935   Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: November 2, 1999   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
End-Stage Renal Disease
Kidney Transplantation
Additional conditions recognized in this trial
Kidney Diseases
Kidney Failure, Chronic
More general conditions related to this trial
Kidney Failure
Renal Insufficiency
Renal Insufficiency, Chronic
Urologic Diseases
Interventions listed in this trial
Intravenous immune globulin (IVIG)
0.1% human albumin
Additional drug interventions recognized in this trial
Antibodies
Gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services